Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
TG Therapeutics›
Website
AddedFeb 19, 2024
UpdatedJun 18, 2026
TG Therapeutics

TG Therapeutics

Public

TG Therapeutics: A biopharmaceutical firm innovating cancer treatments, focusing on non-Hodgkins lymphoma.

HQ
New York City, NY, US
Founded
1993
Loading
Overview
Compare
Fundraising
Employees
Website

TG Therapeutics - Website

An index of every page on tgtherapeutics.com, by section.

16 pages across 5 sections · Updated Jul 15, 2026·

Homepage

TG Therapeutics's front door: current positioning and top-line messaging.

tgtherapeutics.com
  • Homepage

ContactContact Us

Sales, support, and partnership channels for reaching TG Therapeutics directly.

tgtherapeutics.com/contact-us

ComparisonComparison of Cell Lysis Mediated by Lfb R603 with That Mediated by Ofatumumab Against Cells Expressing Low Levels of Cd20

6 comparison pages published by TG Therapeutics.

  • Comparison of Cell Lysis Mediated by Lfb R603 with That Mediated by Ofatumumab Against Cells Expressing Low Levels of Cd20
  • Ublituximab Tgtx 1101 a Novel Third Generation Anti Cd20 Antibody Demonstrates Enhanced Antitumor Activity Compared to Rituximab in Primary Cns and Intraocular Lymphoma Murine Models
  • Comparison of the Pi3k Delta Inhibitors Tgr1202 and Gs 1101 in Inducing Cytotoxicity and Inhibiting Phosphorylation of Akt in Cll Cells in Vitro
  • Phase 3 Study of Umbralisib Combined with Ublituximab vs Obinutuzumab Plus Chlorambucil in Patients with Chronic Lymphocytic Leukemia Results from Unity Cll
  • Video Phase 3 Study of Umbralisib Combined with Ublituximab vs Obinutuzumab Plus Chlorambucil in Patients with Chronic Lymphocytic Leukemia Results from Unity Cll
  • Efficacy and Safety of Ublituximab vs Teriflunomide in Patients with Relapsing Multiple Sclerosis Results from Two Phase 3 Studies Ultimate I Ultimate Ii American Academy of Neurology

AboutAbout Us

Company story, mission, and background as TG Therapeutics tells it.

tgtherapeutics.com/about-us
  • Message from Our CEO/about-us/message-from-our-ceo
  • Guiding Principles/about-us/guiding-principles
  • Fellowship Program/about-us/fellowship-program
  • Board Members/about-us/board-members
  • Leadership Team/about-us/leadership-team

PrivacyPrivacy Policy

How TG Therapeutics collects, uses, and safeguards data: the canonical policy set.

tgtherapeutics.com/privacy-policy